AR016437A1 - Derivados de acilguanidina como inhibidores de resorcion osea y como antagonistas del receptor vitronectina, procedimiento para su preparacion ypreparacion farmaceutica que los comprenden - Google Patents
Derivados de acilguanidina como inhibidores de resorcion osea y como antagonistas del receptor vitronectina, procedimiento para su preparacion ypreparacion farmaceutica que los comprendenInfo
- Publication number
- AR016437A1 AR016437A1 ARP980106446A ARP980106446A AR016437A1 AR 016437 A1 AR016437 A1 AR 016437A1 AR P980106446 A ARP980106446 A AR P980106446A AR P980106446 A ARP980106446 A AR P980106446A AR 016437 A1 AR016437 A1 AR 016437A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- radical
- unsubstituted
- substituted
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 150000003254 radicals Chemical class 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- -1 alkylene radical Chemical class 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 abstract 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 abstract 1
- 102100022337 Integrin alpha-V Human genes 0.000 abstract 1
- 108010048673 Vitronectin Receptors Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 150000005840 aryl radicals Chemical class 0.000 abstract 1
- 239000002617 bone density conservation agent Substances 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Derivados de acilguanidinas, que comprenden un compuesto de la formula (I) donde, R1 y R2 independientemente uno de otro son hidrogeno o alquilo C1-6 quees insustituido o sustituido por R3, siempre y cuando R1 y R2 no sean ambos hidrogeno al mismo tiempo, o donde los radicales R1 y R2 juntos son un radicalalquileno C2-9, bivalente saturado o insaturado, que es insustituido o es sustituido por uno o más grupos del grupo formado por halogeno, alquilo C1-6, alcoxiC1-6, arilo C6-14, arilo C6-14-alquilo C1-6, heteroarilo C5-14, heteroarilo C5-14-alquilo C1-6, cicloalquilo C3-12, cicloalquilo C3-12-alquilo C1-6 y oxo,donde un anillo saturado o insaturado de 5 a 7 miembros, que es insustituido o sustituido por R3 y que es un anillo carbocíclico oun anillo heterocíclico quecontiene uno o dos átomos de nitrogeno anulares que pueden estar fusionados a un enlace carbono-carbono en el radical alquileno C2-9; R3 es alquilo C1-8,alcoxi C1-8, arilo C5-14, arilo C5-14-alquilo C1-4, halogeno, trifluormetilo, hidroxilo, nitro o amino; R4 es hidrogeno, alquilo (C1-6)-CO-O-alquilo C1-4 oalquilo C1-6, que es insustituido o sustituido por un radical del grupo formado por hidroxilo, alcoxi C1-4, alquilo (C1-4)-S(O)2-, NR7R7 y N+R7R7R7 Q-,donde R7, R7 yR7 independientemente uno del otro, son hidrogeno, alquilo C1-6, arilo C5-14, o arilo C5-14-alquilo C1-6 y Q- es un anion fisiologicamentetolerable, o donde R4 es uno de los radicales del grupo (II), donde los enlaces, via los cuales los radicales se unen, se indican mediante guiones; R5 esalquilo C1-8, arilo C6-14-alquilo c1-6 o heteroarilo C5-14-alquilo C1-6, donde el radical arilo o el radical heteroarilo es insustituido o sustituido por uno,dos o tres radicales R3; R6 es hidrogeno, alquilo(C1-6)-O-CO-, hidroxilo, alquilo (C1-6)-O-CO-O o nitro; A es Ch2, O, S o NH; m es 1, 2 o 3; n es 0 o 1; entodas sus formas estereoisoméricas y mezclas de los mismos en todas las proporciones y sus sales fisiologicamente tolerables y sus prodrogas. Los compuestos dela formula (I) son ingredientes activos farmacéuticamente valiosos. Los mismos son antagonistas del receptor vitronectina e inhibidores de la resorcion osea
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97122520A EP0933367A1 (en) | 1997-12-19 | 1997-12-19 | Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR016437A1 true AR016437A1 (es) | 2001-07-04 |
Family
ID=8227841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106446A AR016437A1 (es) | 1997-12-19 | 1998-12-17 | Derivados de acilguanidina como inhibidores de resorcion osea y como antagonistas del receptor vitronectina, procedimiento para su preparacion ypreparacion farmaceutica que los comprenden |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US6492356B1 (es) |
| EP (2) | EP0933367A1 (es) |
| JP (1) | JP2001526271A (es) |
| KR (1) | KR20010033281A (es) |
| CN (1) | CN1205191C (es) |
| AP (1) | AP2000001842A0 (es) |
| AR (1) | AR016437A1 (es) |
| AT (1) | ATE228112T1 (es) |
| AU (1) | AU753109B2 (es) |
| BG (1) | BG64754B1 (es) |
| BR (1) | BR9814308A (es) |
| CA (1) | CA2312712A1 (es) |
| CU (1) | CU23032A3 (es) |
| DE (1) | DE69809594T2 (es) |
| DK (1) | DK1042301T3 (es) |
| EA (1) | EA002921B1 (es) |
| ES (1) | ES2186251T3 (es) |
| HR (1) | HRP20000412A2 (es) |
| HU (1) | HUP0104912A3 (es) |
| ID (1) | ID26248A (es) |
| IL (1) | IL136858A0 (es) |
| MY (1) | MY122269A (es) |
| NO (1) | NO317420B1 (es) |
| NZ (1) | NZ504954A (es) |
| PL (1) | PL341216A1 (es) |
| PT (1) | PT1042301E (es) |
| SI (1) | SI1042301T1 (es) |
| SK (1) | SK9032000A3 (es) |
| TR (1) | TR200001964T2 (es) |
| TW (1) | TW446705B (es) |
| WO (1) | WO1999032457A1 (es) |
| YU (1) | YU39000A (es) |
| ZA (1) | ZA9811571B (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6313119B1 (en) | 1998-01-23 | 2001-11-06 | Adventis Pharma Deutschland Gmbh | Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| AU747784B2 (en) * | 1998-07-29 | 2002-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| EP1028114A1 (en) | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| EP1065207A1 (en) | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them |
| EP1070707A1 (en) * | 1999-07-21 | 2001-01-24 | Aventis Pharma Deutschland GmbH | 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
| US6849639B2 (en) | 1999-12-14 | 2005-02-01 | Amgen Inc. | Integrin inhibitors and their methods of use |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| JP2003531141A (ja) | 2000-04-17 | 2003-10-21 | セルテック アール アンド ディ リミテッド | エナミン誘導体 |
| FR2808798A1 (fr) * | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | Nouveaux derives antagonistes du recepteur de la vitronectine |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| WO2002004426A1 (en) | 2000-07-07 | 2002-01-17 | Celltech R & D Limited | Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists |
| EP1176145A1 (en) * | 2000-07-28 | 2002-01-30 | Aventis Pharma Deutschland GmbH | Novel guanidino derivatives as inhibitors of cell adhesion |
| JP2004505110A (ja) | 2000-08-02 | 2004-02-19 | セルテック アール アンド ディ リミテッド | ３位置換イソキノリン−１−イル誘導体 |
| EP1197488A1 (en) | 2000-10-10 | 2002-04-17 | Aventis Pharma Deutschland GmbH | (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use |
| FR2847254B1 (fr) * | 2002-11-19 | 2005-01-28 | Aventis Pharma Sa | Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant |
| FR2870541B1 (fr) * | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| FR2873585B1 (fr) * | 2004-07-27 | 2006-11-17 | Aventis Pharma Sa | Nouvelles formulations galeniques de principes actifs |
| US20060039949A1 (en) * | 2004-08-20 | 2006-02-23 | Nycz Jeffrey H | Acetabular cup with controlled release of an osteoinductive formulation |
| US20060057184A1 (en) * | 2004-09-16 | 2006-03-16 | Nycz Jeffrey H | Process to treat avascular necrosis (AVN) with osteoinductive materials |
| US9119901B2 (en) * | 2005-04-28 | 2015-09-01 | Warsaw Orthopedic, Inc. | Surface treatments for promoting selective tissue attachment to medical impants |
| US8414907B2 (en) | 2005-04-28 | 2013-04-09 | Warsaw Orthopedic, Inc. | Coatings on medical implants to guide soft tissue healing |
| US20070077267A1 (en) * | 2005-10-03 | 2007-04-05 | Sdgi Holdings, Inc. | Bioactive composite implants |
| US20070280986A1 (en) * | 2006-06-01 | 2007-12-06 | Carlos Gil | Intra-operative coating of implants |
| US8133553B2 (en) | 2007-06-18 | 2012-03-13 | Zimmer, Inc. | Process for forming a ceramic layer |
| US8309521B2 (en) | 2007-06-19 | 2012-11-13 | Zimmer, Inc. | Spacer with a coating thereon for use with an implant device |
| US8608049B2 (en) | 2007-10-10 | 2013-12-17 | Zimmer, Inc. | Method for bonding a tantalum structure to a cobalt-alloy substrate |
| WO2009096945A1 (en) * | 2008-01-29 | 2009-08-06 | Zimmer, Inc. | Implant device for use in an implant system |
| WO2015181676A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Carbonitrile derivatives as selective androgen receptor modulators |
| US11020160B2 (en) | 2016-03-21 | 2021-06-01 | Warsaw Orthopedic, Inc. | Surgical injection system and method |
| US10709814B2 (en) | 2016-04-22 | 2020-07-14 | Warsaw Orthopedic, Inc. | Osteoimplant comprising an insoluble fibrous polymer |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217994A (en) * | 1991-08-09 | 1993-06-08 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives |
| US5204350A (en) * | 1991-08-09 | 1993-04-20 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives |
| WO1994008577A1 (en) * | 1992-10-14 | 1994-04-28 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| JPH08504194A (ja) * | 1992-12-01 | 1996-05-07 | メルク エンド カンパニー インコーポレーテッド | フィブリノーゲンレセプターアンタゴニスト |
| JP3895792B2 (ja) * | 1995-12-08 | 2007-03-22 | プロスケリア・エス・ア・エス | 骨形成促進剤 |
-
1997
- 1997-12-19 EP EP97122520A patent/EP0933367A1/en not_active Withdrawn
-
1998
- 1998-08-27 TW TW087110508A patent/TW446705B/zh not_active IP Right Cessation
- 1998-12-10 ID IDW20001175A patent/ID26248A/id unknown
- 1998-12-10 YU YU39000A patent/YU39000A/sh unknown
- 1998-12-10 EA EA200000682A patent/EA002921B1/ru not_active IP Right Cessation
- 1998-12-10 BR BR9814308-5A patent/BR9814308A/pt not_active Application Discontinuation
- 1998-12-10 ES ES98966287T patent/ES2186251T3/es not_active Expired - Lifetime
- 1998-12-10 JP JP2000525394A patent/JP2001526271A/ja not_active Abandoned
- 1998-12-10 CU CU20000149A patent/CU23032A3/es unknown
- 1998-12-10 US US09/581,915 patent/US6492356B1/en not_active Expired - Fee Related
- 1998-12-10 EP EP98966287A patent/EP1042301B1/en not_active Expired - Lifetime
- 1998-12-10 CN CNB988136112A patent/CN1205191C/zh not_active Expired - Fee Related
- 1998-12-10 DE DE69809594T patent/DE69809594T2/de not_active Expired - Fee Related
- 1998-12-10 TR TR2000/01964T patent/TR200001964T2/xx unknown
- 1998-12-10 AU AU22700/99A patent/AU753109B2/en not_active Ceased
- 1998-12-10 NZ NZ504954A patent/NZ504954A/en unknown
- 1998-12-10 DK DK98966287T patent/DK1042301T3/da active
- 1998-12-10 HR HR20000412A patent/HRP20000412A2/hr not_active Application Discontinuation
- 1998-12-10 IL IL13685898A patent/IL136858A0/xx not_active IP Right Cessation
- 1998-12-10 KR KR1020007006722A patent/KR20010033281A/ko not_active Ceased
- 1998-12-10 PT PT98966287T patent/PT1042301E/pt unknown
- 1998-12-10 SK SK903-2000A patent/SK9032000A3/sk unknown
- 1998-12-10 PL PL98341216A patent/PL341216A1/xx not_active Application Discontinuation
- 1998-12-10 WO PCT/EP1998/008051 patent/WO1999032457A1/en not_active Ceased
- 1998-12-10 HU HU0104912A patent/HUP0104912A3/hu unknown
- 1998-12-10 CA CA002312712A patent/CA2312712A1/en not_active Abandoned
- 1998-12-10 SI SI9830345T patent/SI1042301T1/xx unknown
- 1998-12-10 AP APAP/P/2000/001842A patent/AP2000001842A0/en unknown
- 1998-12-10 AT AT98966287T patent/ATE228112T1/de not_active IP Right Cessation
- 1998-12-17 AR ARP980106446A patent/AR016437A1/es unknown
- 1998-12-17 ZA ZA9811571A patent/ZA9811571B/xx unknown
- 1998-12-18 MY MYPI98005741A patent/MY122269A/en unknown
-
2000
- 2000-06-16 NO NO20003118A patent/NO317420B1/no unknown
- 2000-06-19 BG BG104544A patent/BG64754B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR016437A1 (es) | Derivados de acilguanidina como inhibidores de resorcion osea y como antagonistas del receptor vitronectina, procedimiento para su preparacion ypreparacion farmaceutica que los comprenden | |
| AR047008A1 (es) | Compuestos de 4-tetrazolil-4-fenilpiperidina como agonistas de los receptores opioides y agentes terapeuticos de utilidad para el tratamiento del dolor y composiciones farmaceuticas que los contienen como principio activo en combinacion con otros agentes terapéuticos. | |
| ES2032024T3 (es) | Procedimiento para preparar derivados de quinazolina. | |
| AR043938A1 (es) | Compuesto heterociclico derivado de quinolina o naftiridina, composicion farmaceutica que lo comprende y su uso para preparar esta ultima | |
| ES2104946T3 (es) | Ureas ciclicas y similares utiles como inhibidores de la proteasa retrovirica. | |
| AR016762A1 (es) | Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo | |
| AR033383A1 (es) | Derivados de acridina, procedimiento para prepararlos, el uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados | |
| AR049092A1 (es) | Derivados de tetrahidronaftiridina como ligandos del receptor h3 de histamina | |
| AR010396A1 (es) | Compuestos de quinolina y de quinazolina utiles en terapia, formulacion farmaceutica que los contiene, su uso en la fabricacion de un medicamento,procedimiento para su produccion y compuestos utiles en dicho procedimiento | |
| ES2038660T3 (es) | Un procedimiento para la preparacion de nuevos benzopiranos con actividad farmacologica. | |
| PE20021010A1 (es) | Derivados espirociclicos como inhibidores de fosfodiesterasa-7 | |
| ES2055860T3 (es) | Derivados 2-aminopirimidinona. | |
| AR039189A1 (es) | Compuesto de pirrolopiridazina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| AR035325A1 (es) | Derivados de adamantano, un proceso para su preparacion, composicion farmaceutica, un proceso para la preparacion de dicha composicion, y el uso de dichos derivados para la fabricacion de un medicamento | |
| ES2031876T3 (es) | Un procedimiento para la preparacion de 5,6-dihidro-2-(fenil sustituido)-1,2,4,-triazin-3,5(2h,4h)-dionas. | |
| AR037181A1 (es) | Compuesto de 4-heteroaril-(5-miembros) acil pirrolidina, formulacion farmaceutica que lo comprende, uso del mismo para preparar un medicamento y procedimiento para su preparacion | |
| AR014456A1 (es) | Derivados de sulfonamida como inhibidores de la resorcion osea y como inhibidores de la adhesion celular, un proceso para su preparacion ycomposicion farmaceutica que los contienen | |
| ES2061462T3 (es) | Compuestos cefemo, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
| ES2009785B3 (es) | Procedimiento para preparar derivados de tioxantona. | |
| PE20240107A1 (es) | Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterociclicos farmacologicamente activos | |
| ES2196213T3 (es) | Derivados de benzoxazoles como activadores parciales del receptor de serotonina 5-ht3. | |
| BRPI0016638B8 (pt) | compostos análogos de homopiperidilbenzimidazóis substituídos como relaxantes fúndicos, processo para preparar os mesmos, composição farmacêutica e processo para prepará-la. | |
| AR009732A1 (es) | Bisindolilmaleimidas, proceso para su preparacion, su uso en la preparacion de medicamentos, una composicion farmaceutica que los contiene y compuestosintermediarios para su uso exclusivo en el mencionado proceso | |
| PT1101765E (pt) | Novos compostos analogos da camptotecina, processo para a sua preparacao e as composicoes farmaceuticas que os contem | |
| AR039008A1 (es) | Derivados azabiciclicos, azatriciclicos y azaespirociclicos de aminociclohexano antagonistas de los receptores nmda, 5-ht3, y nicotinico neuronal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |